Table 1 Patient characteristics
Characteristics | Data |
|---|---|
Total number of patients | 190 |
Age, yr | 51 (18–84) |
Menopausal status | Â |
 Premenopausal | 87 (46 %) |
 Perimenopausal | 24 (13 %) |
 Postmenopausal | 79 (42 %) |
Histologic findings | Â |
 Ductal | 140 (74 %) |
 Lobular | 22 (12 %) |
 Other | 24 (13 %) |
 Unknown | 4 (2 %) |
Tumor grading | Â |
 G1 | 13 (7 %) |
 G2 | 85 (45 %) |
 G3 | 88 (46 %) |
 Unknown | 4 (2 %) |
Tumor size before NACT | Â |
 cT1a–cT1c | 46 (24 %) |
 cT2 | 111 (58 %) |
 Above cT2 | 29 (15 %) |
 Unknown | 4 (2 %) |
Tumor size after NACT | Â |
 ypT0(is) | 46/177 (26 %) |
 ypT1a–ypT1c | 71/177 (40 %) |
 ypT2 | 47/177 (27 %) |
 Above ypT2 | 13/177 (7 %) |
 Unknown | 13/190 |
Nodal status before NACT | Â |
 cN0 | 94 (49 %) |
 cN1 | 83 (44 %) |
 cN2, cN3 | 10 (5 %) |
 Unknown | 3 (2 %) |
Nodal status after NACT | Â |
 yN0 | 116/180 (64 %) |
 yN1 | 48/180 (27 %) |
 yN2,N3 | 16/180 (9 %) |
 Unknown | 10/190 |
Estrogen receptor | Â |
 Positive | 131 (69 %) |
 Negative | 58 (31 %) |
 Unknown | 1 (1 %) |
Progesterone receptor | Â |
 Positive | 116 (61 %) |
 Negative | 73 (38 %) |
 Unknown | 1 (1 %) |
HER2 status | Â |
 Positive | 56 (29 %) |
 Negative | 133 (70 %) |
 Unknown | 1 (1 %) |
Tumor subtype (IHC) | Â |
 ER−, PR−, HER2− | 36 (19 %) |
 ER−, PR−, HER2+ | 15 (8 %) |
 ER+/PR+, HER2− | 97 (51 %) |
 ER+, PR+, HER2+ | 41 (22 %) |
 Unknown/n.a. | 1 (1 %) |
Pathological response | Â |
 Complete response | 37/176 (21 %) |
 Partial response | 127/176 (72 %) |
 No response | 12/176 (7 %) |
 Unknown | 14 (7 %) |
DTC positive | Â |
 Before therapy | 38/142 (27 %) |
 After therapy | 33/165 (20 %) |
CTC positive | Â |
 Before therapy | 32/135 (24 %) |
 After therapy | 11/133 (8 %) |
slCTC positive | Â |
 Before therapy | 46/91 (51 %) |
 After therapy | 18/90 (20 %) |
DTC and/or CTC positive | Â |
 Before therapy | 59/136 (43 %) |
 After therapy | 44/140 (34 %) |
DTC and/or slCTC-pos. | Â |
 Before therapy | 74/107 (69 %) |
 After therapy | 48/103 (47 %) |
CTC and/or slCTC positive | Â |
 Before therapy | 57/92 (62 %) |
 After therapy | 25/89 (28 %) |
Survival | Â |
 OS | 54 mo (2–93 mo) |
 Alive | 169 (89 %) |
 Dead | 19 (10 %) |
 Unknown | 2 (1 %) |
 PFS | 52 mo (2–93 mo) |
Recurrence | Â |
 Alive without relapse | 135 (71 %) |
 Relapse | 22 (12 %) |
 Unknown | 33 (17 %) |